Inventor

DIMITROV DIMITER S

US81 patents

⚠️ This page may combine multiple inventors who share the name “DIMITROV DIMITER S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

DIMITROV DIMITER S

US HEALTH

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

Mesothelin antibodies and methods for eliciting potent antitumor activity

Human anti-mesothelin monoclonal antibodies

Human monoclonal antibodies against Hendra and Nipah viruses

M971 chimeric antigen receptors

Human monoclonal antibodies specific for CD22

HER2-specific monoclonal antibodies and conjugates thereof

Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Antibody-drug conjugates for targeting CD56-positive tumors

Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof

M971 chimeric antigen receptors

Engineered antibody constant domain molecules

Soluble engineered monomeric Fc

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

M971 chimeric antigen receptors

Anti-HIV domain antibodies and method of making and using same

LENTIGEN TECH INC

Compositions and methods for treating cancer with anti-CD123 immunotherapy

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

Compositions and methods for treating cancer with anti-CD33 immunotherapy

Compositions and methods for treating cancer with anti-CD38 immunotherapy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

Compositions and methods for treating cancer with anti-CD19 immunotherapy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

Compositions and methods for treating cancer with anti-ROR1 immunotherapy

Compositions and methods for treating cancer with anti-CD38 immunotherapy

Compositions and methods for treating cancer with anti-CD123 immunotherapy

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

Compositions and methods for treating cancer with anti-CD19 immunotherapy

Compositions and methods for treating cancer with anti-CD33 immunotherapy

DIMITROV DIMITER S

Human monoclonal antibodies specific for CD22

Engineered antibody constant domain molecules

Human monoclonal antibodies that bind human insulin like growth factors and their use

Anti-HIV domain antibodies and method of making and using same

High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins

Human monoclonal antibodies against hendra and nipah viruses

Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II

MEMORIAL SLOAN KETTERING CANCER CENTER

Antigen-binding proteins targeting CD56 and uses thereof

Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors

Mesothelin-targeted chimeric antigen receptors and uses thereof

Mesothelin-targeted chimeric antigen receptors and methods of making them

PURDUE RESEARCH FOUNDATION

Anti-human folate receptor beta antibodies and methods of use

SCRIPPS RESEARCH INST

Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes

LENTIGENTECHNOLOGY INC

Compositions and methods for treating cancer with anti-CD22 immunotherapy

THE US SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES

Human monoclonal antibodies specific for CD22

HO MITCHELL

Human monoclonal antibodies specific for glypican-3 and use thereof

AMEMIYA KEI

Human monoclonal antibodies protective against bubonic plague

THE US SECRETARY DEPARTMENT OF HEALTH

Anti-CD276 antibodies (B7H3)

THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

THE GOVERNMENT OF THE U S A AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES

Human monoclonal antibodies specific for CD22